#USA #Boston #Aisa Pharma #AISA-021 #Cilnidipine

Aisa Pharma's Successful Phase 2 Trial of AISA-021 for Raynaud's Phenomenon

Aisa Pharma, a biopharmaceutical company specializing in rare disease therapies, has announced encouraging results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine) for systemic sclerosis-associated Raynaud's phenomenon (SSc RP). Conducted at the 9th World Systemic Sclerosis Congress in Athens, Greece, these results are pivotal in understanding treatment options for this challenging condition.

Key Findings from the RECONNOITER Trial

The trial involved a randomized and double-blind design, assessing 64 patients suffering from SSc-related Raynaud's symptoms. Participants were given AISA-021, a novel once-daily calcium channel blocker, alongside their standard care. The study aimed to evaluate both safety and efficacy, and while statistical significance on the primary efficacy endpoint was not achieved, the observed trends are promising.

Significant improvements were noted in several areas:

• - AISA-021 resulted in a 22.1% reduction in the weekly frequency of Raynaud's attacks compared to a 12.4% reduction in the placebo group, although this did not meet the threshold for statistical significance (p = 0.10).
• - Most notably, patients taking AISA-021 experienced a greater than 155% increase in the number of attack-free days, with proportions nearing four times that of baseline (p = 0.013).
• - The duration of Raynaud's attacks was also significantly reduced (p = 0.02), alongside improvements in associated pain and other symptoms related to SSc.

Patients reported a generally favorable safety profile with AISA-021, with no serious treatment-related adverse events, indicating that the treatment could be well-tolerated.

Perspectives from the Medical Community

Dr. Andrew Sternlicht, Aisa Pharma’s CEO, expressed optimism regarding the trial's outcomes. He emphasized the need for new therapeutic options for Raynaud's phenomenon, which is a debilitating condition affecting numerous SSc patients without any approved treatment. Professor Francesco Del Galdo from Leeds University also noted the relevance of the improvements seen, suggesting that the treatment could be pivotal in changing the lives of patients.

Future Directions

Building on these findings, Aisa Pharma plans to engage in discussions with the U.S. Food and Drug Administration (FDA) regarding the design of Phase 3 studies and potential pathways for registration. The success of AISA-021 could serve as a foundation for addressing other conditions tied to systemic sclerosis, such as gastrointestinal symptoms and pulmonary issues, thereby broadening its therapeutic applications.

Understanding Raynaud's Phenomenon

Raynaud's phenomenon, which affects approximately 95% of systemic sclerosis patients, leads to severe symptoms like pain and numbness due to limited blood flow, often triggered by cold exposure. The ailment significantly affects the quality of life, making the development of effective treatments a critical goal.

Conclusion

Aisa Pharma continues to pave the way towards enhancing the lives of those affected by systemic sclerosis and its related complications. The positive results from the RECONNOITER trial are not just a milestone for the company but for countless patients who have long awaited viable treatment options. As further studies progress, the hope for transforming the management of Raynaud's phenomenon could soon become a reality.